Edita Botonjic-Sehic
Head of Process Analytical Technology & Data Science ReciBioPharm
Dr. Edita Botonjic-Sehic is a Head of process analytics, data engineering and data science at ReciBioPharm where she provides technical insight and strategic conceptualization and implementation of process analytical technology (PAT), data engineering and data science for the continuous bioprocessing; she brings more than 20 years of experience in advanced process analytical technologies and data science techniques improving manufacturing concepts in pharmaceutical and therapeutics development.
Prior to joining ReciBioPharm, Dr. Botonjic-Sehic was a Director of process analytical technology at Pall Life Sciences and Cytiva (Danaher operational companies) leading development of novel technologies. Additionally she was a member of the PAT team within GlaxoSmithKline’s program for API development and she also led a PAT team at TEVA Pharmaceuticals for drug product manufacturing, and was a principal investigator and program manager on several government-funded (DHS, TSWG, CTTSO) projects at Morpho Detection (formerly GE Homeland Security), where she specifically worked on the development of systems for trace and bulk materials detection.
Dr. Botonjic-Sehic completed her PhD in Analytical Chemistry at the University of Rhode Island after undergraduate studies at Assumption College in both chemistry and mathematics and recently has completed business analytics program at Harvard Business School.
Seminars
- Integrating PAT data with AI and digital twins and harmonizing and contextualizing analytics to enable actionable insights and faster, better informed manufacturing decisions with less reliance on offline testing
- Developing and validating digital twins using FDA funded programs and regulator endorsed methodologies to gain regulatory confidence in advanced models, reduce risk and accelerate adoption in GMP manufacturing
- Replacing traditional analytical benchmarks with PAT and model-based approaches developed in collaboration with regulators to establish modern acceptance criteria that support successful filings while future proofing process control strategies
